IART250117C17500
- 0.00
- 0.000.00%
Integra Lifesciences Newsroom
BTIG Maintains Integra Lifesciences(IART.US) With Hold Rating
BTIG Maintains Integra Lifesciences(IART.US) With Hold Rating
Sell Rating Issued for Integra Lifesciences Amidst FDA Warning and Leadership Changes
BofA Securities Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $21
Wells Fargo Maintains Integra Lifesciences(IART.US) With Hold Rating
Wells Fargo Sticks to Its Hold Rating for Integra Lifesciences (IART)
Morgan Stanley Initiates Integra Lifesciences(IART.US) With Sell Rating, Announces Target Price $20
J.P. Morgan Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $24
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Maintains Target Price $26
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Raises Target Price to $26
Integra LifeSciences Is Maintained at Sell by Citigroup
Integra Lifesciences Analyst Ratings
Morgan Stanley Remains a Sell on Integra Lifesciences (IART)
JMP Securities Maintains Integra Lifesciences(IART.US) With Buy Rating, Maintains Target Price $35
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Integra Lifesciences (IART)
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Cuts Target Price to $21
Integra Lifesciences Analyst Ratings
Truist Raises Price Target on Integra LifeSciences Holdings to $26 From $21, Keeps Hold Rating
B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18
Integra LifeSciences Upgraded to Neutral From Sell at BTIG